pharmaphorum

Sanofi gets double blow for MS drug tolebrutinib

Shares in Sanofi were sliding today after a double dose of bad news for its oral BTK inhibitor tolebrutinib, in development as a therapy for multiple sclerosis (MS). Along with what looks set to be ...
pharmaphorum

No Christmas present for Sanofi, as FDA turns down MS drug

Sanofi went into the Christmas break with news of a takeover deal to boost its vaccines business, even as the FDA sent an early complete response letter for its oral multiple sclerosis candidate ...
FierceBiotech

Roche unveils data behind BTK inhibitor's phase 3 multiple sclerosis win in Ocrevus trial

Roche has shared the numbers behind its phase 3 win in primary progressive multiple sclerosis (PPMS), linking its BTK inhibitor to a 12% reduction in the risk of disability progression compared to ...
BioSpace

Genentech’s Fenebrutinib Is the First Investigational Medicine in Over a Decade That Reduces Disability Progression in Primary Progressive Multiple Sclerosis (PPMS)

– Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority compared to the current standard of care, Ocrevus, in ...
Reuters

Roche's multiple sclerosis drug fenebrutinib meets goal in late-stage trial

BERLIN, Feb 7 (Reuters) - Swiss pharmaceutical company Roche (ROG.S), opens new tab said on Saturday its experimental multiple sclerosis drug fenebrutinib met the main goal in a late-stage trial in ...
Morningstar

Genentech’s Fenebrutinib Is the First Investigational Medicine in Over a Decade That Reduces Disability Progression in Primary Progressive Multiple Sclerosis (PPMS)

Genentech’s Fenebrutinib Is the First Investigational Medicine in Over a Decade That Reduces Disability Progression in Primary Progressive Multiple Sclerosis (PPMS) – Late-breaking Phase III FENtrepid ...
The Bakersfield Californian

Genentech’s Fenebrutinib Is the First Investigational Medicine in Over a Decade That Reduces Disability Progression in Primary Progressive Multiple Sclerosis (PPMS)

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new late-breaking data from the Phase III FENtrepid study showing the investigational Bruton’s tyrosine kinase (BTK ...